TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note released on Sunday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Down 5.4 %

TXMD opened at $1.57 on Friday. The company has a fifty day simple moving average of $1.98 and a 200 day simple moving average of $2.17. TherapeuticsMD has a twelve month low of $1.57 and a twelve month high of $4.35.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Friday, May 10th. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $0.31 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TherapeuticsMD stock. ADAR1 Capital Management LLC acquired a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned about 2.57% of TherapeuticsMD as of its most recent SEC filing. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.